Table 5.
Medication and medical approaches in inflammatory bowel disease patients
| Medication | (n=329) | CD (n=212) | UC (n=117) | |
|---|---|---|---|---|
| Anti-TNF | 185 (56.2) | 133 (62.7) | 52 (44.4) | 0.001a |
| 5 AZA | 146 (44.4) | 95 (44.8) | 51 (43.6) | 0.831a |
| Humira | 145 (44.1) | 104 (49.1) | 41 (35.0) | 0.014a |
| AZA | 106 (31.9) | 71 (33.5) | 34 (29.1) | 0.409a |
| IFX | 96 (29.2) | 73 (34.4) | 23 (19.7) | 0.005a |
| Cipro | 45 (13.7) | 37 (17.5) | 8 (6.8) | 0.007a |
| Flagyl | 45 (13.7) | 37 (17.5) | 8 (6.8) | 0.007a |
| Probiotics | 28 (8.5) | 23 (10.9) | 5 (4.3) | 0.041a |
| MTX | 10 (3.0) | 10 (4.7) | 0 (0.0) | 0.016b |
| Vedo | 7 (2.1) | 7 (3.3) | 0 (0.0) | 0.054b |
| Hyperbaric O2 | 6 (1.8) | 6 (2.8) | 0 (0.0) | 0.093b |
| Ciclo sp | 2 (0.6) | 0 (0.0) | 2 (1.7) | 0.126b |
| Tacrolimus | 1 (0.3) | 0 (0.0) | 1 (0.9) | 0.356b |
| Stem cell therapy | 1 (0.3) | 1 (0.5) | 0 (0.0) | 1.000b |
Notes:
a
Descriptive level of probability of chi-squared test.
b
Descriptive level of probability of Fisher’s exact test. Data are presented as n (%).
Abbreviations: 5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; UC, ulcerative colitis; IFX, Infliximab; MTX, methotrexate; Vedo, vedolizumab; Cico sp, Ciprofloxacin.